Additionally, on days 11 and 18 post-tumor implantation (1 and 8 days after the last i.v. injection with anti-CD8, respectively) lower Cd8b levels in the blood were observed due to the depletion, while this was not the case on day 7 (3 days before rIL-12 treatment and 2 days before the first injection with anti-CD8), indicating that our regimen was sufficient for successful depletion overtime (Figure S3O). The gene discussed is CD8A; the disease is neoplasm.